Jessica Perazzelli

发表

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

David Allman, Nicole M Martinez, Matthew R. Gazzara, 2015, Cancer discovery.

Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells

Yong Gu Lee, Nathan H. Roy, S. Grupp, 2021, Nature Network Boston.

Dual CD 19 and CD 123 targeting prevents antigen-loss relapses after CD 19-directed immunotherapies

S. Grupp, D. Porter, M. Kalos, 2019 .

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

S. Grupp, D. Porter, M. Kalos, 2016, The Journal of clinical investigation.

Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells

S. Grupp, D. Porter, C. June, 2015, Journal of Immunotherapy for Cancer.

A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor positive cells.

C. June, J. Melenhorst, D. Barrett, 2019, Blood.

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015).

S. Grupp, J. Gartner, S. Rosenberg, 2015, Journal for immunotherapy of cancer.

Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies

S. Grupp, D. Barrett, Jessica Perazzelli, 2016, Science Translational Medicine.

Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing

Gregory M. Chen, S. Grupp, D. Barrett, 2022, Cancer immunology research.

Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response

D. Weissman, S. Grupp, A. Resnick, 2019, Human gene therapy.

CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum

S. Grupp, C. Hu, A. Bagashev, 2018, Molecular and Cellular Biology.

Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies

S. Grupp, D. Porter, C. June, 2015 .

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

Nathan H. Roy, S. Grupp, C. June, 2019, Blood.

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

S. Grupp, D. Porter, C. June, 2017 .

Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Syndrome in B-Cell ALL Patients Receiving CART19.

D. Teachey, A. Seif, S. Grupp, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.